Clinical Trial Update: Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of a CD19/CD20 dual-targeted cell therapy in relapsed or refractory B-cell non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Status: TERMINATED